Rosen Law Firm, a global investor rights law firm, reminds purchasers of Keryx Biopharmaceuticals, Inc. securities (NASDAQ:KERX) from February 25, 2016 through August 1, 2016, both dates inclusive (the “Class Period”) of the important October 3, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Keryx Biopharmaceuticals investors under the federal securities laws.

To join the Keryx Biopharmaceuticals class action, go to the firm’s website at http://rosenlegal.com/cases-927.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for more information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product; (2) the issue was resulting in decreased production yields of finished drug product; and (3) as a result, defendants’ statements about Keryx Biopharmaceuticals’ business and operations were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-927.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com. Attorney Advertising. Prior results do not guarantee a similar outcome.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

-------------------------------

Contact Information:

Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 34th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com

Rosen Law Firm866-767-3653Phillip Kim, Esq.pkim@rosenlegal.comorKevin Chan, Esq.kchan@rosenlegal.com

Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.